Companies: 10,795·Total market cap: $144.5T
Elanco Animal Health Incorporated

Elanco Animal Health Incorporated

ELANNYSEHealthcare● Active
$23.63
$-1.08(-4.37%)
Market Cap$11.8B
P/E Ratio
52W High$27.72
52W Low$13.16

Elanco Animal Health Incorporated (ELAN) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

elan · stock forecast · 20 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 20 Wall Street analysts in the past 3 months

SellBuy

Buy

20 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
14
Hold
4
Sell
2
Strong Sell
0
Total: 20 · Buy rate: 70.0%

12-Month Price Target

High

$30.00

Consensus

$28.67

+21.3% upside

Low

$23.00

Median: $30 · Last Close: $23.63

The Elanco Animal Health Incorporated (ELAN) analyst consensus is Buy, based on ratings from 20 Wall Street analysts over the past 3 months. The average 12-month ELAN price target is $28.67, representing +21.3% upside from the current price of $23.63.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $29 (21.3%)

Consensus Target

$28.67

21.3% upside

High Target

$30

27.0%

Low Target

$23

-2.7%

Current Price

$23.63

as of today

Based on analyst price targets, the ELAN stock price prediction for the next 12 months ranges from $23 to $30. The consensus ELAN price forecast of $28.67 implies 21.3% upside from the current price of $23.63.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$24.754.76%

1-day model range: $24.56–$24.95. Peak: $24.95 (+4.76%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$28+17.0%
2028$31+29.8%
2029$33+39.2%
2030$34+45.6%
2031+50.0%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

71%0%29%
10Buy
0Neutral
4Sell
RSI (14)77.4Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · ELAN · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$24.04SELL
MA 10$23.63BUY
MA 20$22.41BUY
MA 50$22.88BUY
MA 100$23.77SELL
MA 200$22.35BUY
Current $ELAN · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$23.96SELL
EMA 10$23.53BUY
EMA 20$23.06BUY
EMA 50$23.03BUY
EMA 100$22.96BUY
EMA 200$21.63BUY
Current $ELAN · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Citigroup2026-05-07
Maintains
BuyBuy
JP Morgan2026-05-07
Maintains
OverweightOverweight
Morgan Stanley2026-02-25
Maintains
Equal WeightEqual Weight
Keybanc2026-02-25
Maintains
OverweightOverweight
Leerink Partners2026-02-24
Maintains
OutperformOutperform
JP Morgan2026-02-19
Maintains
OverweightOverweight
Piper Sandler2026-01-22
Upgrade ↑
NeutralOverweight
Morgan Stanley2025-12-18
Maintains
Equal WeightEqual Weight
UBS2025-11-06
Maintains
BuyBuy
UBS2025-10-20
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Elanco Animal Health Incorporated (ELAN) stock. Of the recent 107 rating actions, 17 were upgrades and 10 were downgrades. 20 analysts currently cover ELAN.

Analyst Recommendation Trends

Buy ratings22
Hold ratings00
Sell ratings00

ELAN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$5.1B

↓ 9.4% YoY

Revenue Next Year

$5.3B

↑ 5.2% YoY

EPS This Year

$1.06

EPS Next Year

$1.19

↑ 12.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ELAN EPS of $1.06 for the current fiscal year, based on estimates from 10 analysts. The ELAN revenue forecast is $5.1B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ELAN stock forecast is supported by two independent data sources: analyst consensus ratings from 20 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ELAN price target is $28.67 (+21.3% upside), with an analyst consensus of Buy.

The ELAN short-term stock prediction for tomorrow is $24.75 (+4.76%). The ELAN stock price prediction for 2027 estimates an average of $28. The ELAN stock prediction for 2030 projects a range of $31–$37.

Elanco Animal Health Incorporated trades on NYSE under the ticker ELAN. The ELAN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 70% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ELAN forecast · 8 questions

According to 20 Wall Street analysts, the average 12-month ELAN price target is $28.67, with a high forecast of $30.00 and a low of $23.00. The median price target is shown in the chart above when available. This implies +21.3% potential upside from the current price of $23.63.

ELAN price targetWhat is ELAN price targetELAN analyst price targetELAN 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.